Stereotactic body radiotherapy (SBRT) is a safe and efficacious treatment option for patients with non-small cell lung cancer (NSCLC) whose tumors measure at least 5 cm, according to a study published in Cancer.1
Researchers led by Vivek Verma, MD, of the University of Nebraska Medical Center in Omaha evaluated data from 92 patients with primary NSCLC who had tumors measuring at least 5 cm and without evidence of distant/lymph node metastasis. Patients had undergone SBRT using up to fractions.
Median follow-up was 12 months, or 15 months among survivors. Median age among patients was 73 years; median tumor size was 5.4 cm.
The researchers found that actuarial local control rates were 95.7% at 1 year and 73.2% at 2 years, while the disease-free survival rates were 72.1% at 1 year and 53.5% at 2 years.
The 1-year disease-specific survival rate was 95.5% and the 2-year disease-specific survival rate was 78.6%. With a median survival rate of 21.4 months, patients had a 1-year overall survival rate of 76.2% and a 2-year overall survival rate of 4.64%.
RELATED: Veliparib + Chemo Fails to Improve OS, PFS in Untreated NSCLC
Upon multivariate analysis, the researchers found that lung cancer history and pre-SBRT positron emission tomography maximum standardized uptake value were associated with overall survival.
Thirty-three percent of post-treatment failures were found in distant tumors, as well as 26% that were local and 23% that occurred elsewhere in the lung.
- Verma V, Shostrom VK, Kumar SS, et al. Multi-institutional experience of stereotactic body radiotherapy for large (≥ centimeters) non-small cell lung tumors. Cancer. 2016 Oct 14. doi: 10.1002/cncr.30375 [Epub ahead of print]